First-Line Nivolumab/Relatlimab vs Nivolumab/Ipilimumab in Advanced Melanoma

Source: The Asco Post , August 2024

In an analysis reported in the Journal of Clinical Oncology, Georgina V. Long, PhD, MBBS, and colleagues performed an indirect comparison of outcomes with first-line nivolumab/relatlimab vs nivolumab/ipilimumab for advanced melanoma using patient-level data from trials supporting approval of the two regimens: RELATIVITY-047 and CheckMate 067, respectively. No direct comparisons of the regimens in this setting have been reported previously.

Study Details
In the comparison, inverse probability of treatment weighting (IPTW) was used to adjust for baseline characteristic differences between patients in the two studies. Minimum follow-up was 33 months in RELATIVITY-047 and 36 months in CheckMate 067.

Key Findings
After IPTW, baseline characteristics were balanced for 339 patients receiving nivolumab/relatlimab and 297 receiving nivolumab/ipilimumab. On investigator assessment, for nivolumab/relatlimab vs nivolumab/ipilimumab, 36-month progression-free survival was 36% vs 39% (hazard ratio [HR] = 1.08, 95% confidence interval [CI] = 0.88–1.33), objective response rates were 48% vs 50% (odds ratio = 0.91, 95% CI = 0.73–1.14), and 36-month melanoma-specific survival was 65% vs 62% (HR = 0.86, 95% CI = 0.67–1.12). Overall survival at 36 months was 57% vs 57% (HR = 0.94, 95% CI = 0.75–1.19).
READ THE ORIGINAL FULL ARTICLE